AR105184A1 - Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos - Google Patents
Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidosInfo
- Publication number
- AR105184A1 AR105184A1 ARP160101961A ARP160101961A AR105184A1 AR 105184 A1 AR105184 A1 AR 105184A1 AR P160101961 A ARP160101961 A AR P160101961A AR P160101961 A ARP160101961 A AR P160101961A AR 105184 A1 AR105184 A1 AR 105184A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight
- tablet
- pharmaceutical
- ranging
- tablet core
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 abstract 3
- 229960003862 vemurafenib Drugs 0.000 abstract 3
- VLMVTMCKGVRPGT-UHFFFAOYSA-N (3-amino-2,6-difluorophenyl)-[5-(4-chlorophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]methanone Chemical compound NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F VLMVTMCKGVRPGT-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical group OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 abstract 2
- 239000007884 disintegrant Substances 0.000 abstract 2
- 239000000945 filler Substances 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 239000000314 lubricant Substances 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 229960002271 cobimetinib Drugs 0.000 abstract 1
- 238000005056 compaction Methods 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000021039 metastatic melanoma Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un proceso para preparar un núcleo de comprimido de unidad de dosis farmacéutica, el proceso comprende: (1) mezclar un fármaco activo farmacéutico en partículas, un relleno intragranular, un disgregante intragranular y un lubricante intragranular para formar una premezcla, en donde el fármaco activo farmacéutico en partículas tiene un D [v, 0,5] de tamaño de partícula que va de aproximadamente 25 mm a aproximadamente 65 mm, de aproximadamente 25 mm a aproximadamente 50 mm o de aproximadamente 30 mm a aproximadamente 40 mm; (2) compactar la premezcla mediante la aplicación de una fuerza de compactación que va de aproximadamente 1 kN/cm a aproximadamente 8 kN/cm, de aproximadamente 2 kN/cm a aproximadamente 5 kN/cm o de aproximadamente 2 kN/cm a aproximadamente 4 kN/cm; (3) triturar y tamizar la premezcla compactada para formar gránulos; y (4) formar los gránulos en comprimidos mediante la aplicación de una fuerza de compresión formadora de comprimidos que va de aproximadamente 5 kN a aproximadamente 20 kN, de aproximadamente 14 kN a aproximadamente 19 kN, de aproximadamente 14 kN a aproximadamente 18 kN o de aproximadamente 8 kN a aproximadamente 13 kN, para formar el núcleo de comprimido de unidad de dosis farmacéutica. Reivindicación 17: El proceso de acuerdo con cualquiera de las reivindicaciones precedentes, en donde el fármaco activo farmacéutico en partículas es hemifumarato de cobimetinib polimorfo Forma A. Reivindicación 25: Un núcleo de comprimido de unidad de dosis farmacéutica, el núcleo de comprimido comprende: (1) aproximadamente 5% en peso o más de un fármaco activo farmacéutico en partículas; (2) un contenido de lubricante, basado en el peso del núcleo de comprimido de unidad de dosis farmacéutica, que va de aproximadamente 0,5% en peso a aproximadamente 5% en peso, de aproximadamente 0,5% en peso a aproximadamente 3% en peso, de aproximadamente 1% en peso a aproximadamente 3% en peso, de aproximadamente 1% en peso a aproximadamente 2,5% en peso, o de aproximadamente 1,5% en peso a aproximadamente 2% en peso; (3) un contenido de disgregante, basado en el peso del núcleo de comprimido de unidad de dosis farmacéutica, que va de aproximadamente 2% en peso a aproximadamente 7% en peso, de aproximadamente 2% en peso a aproximadamente 6% en peso, de aproximadamente 2% en peso a aproximadamente 5% en peso, de aproximadamente 3% en peso a aproximadamente 6% en peso o de aproximadamente 3% en peso a aproximadamente 5% en peso; (4) un contenido de relleno, basado en el peso del núcleo de comprimido de unidad de dosis farmacéutica, que va de aproximadamente 60% en peso a aproximadamente 78% en peso, de aproximadamente 65% en peso a aproximadamente 78% en peso, de aproximadamente 65% en peso a aproximadamente 77% en peso, de aproximadamente 70% en peso a aproximadamente 77% en peso, o de aproximadamente 71% en peso a aproximadamente 75% en peso; y (5) opcionalmente, hasta 10% en peso de un aglutinante. Reivindicación 52: Un producto farmacéutico que comprende: (1) un primer comprimido de acuerdo con cualquiera de las reivindicaciones 41, 42 ó 46 a 48; y (2) un segundo comprimido que comprende {3-[5-(4-clorofenil)-1H-pirrolo[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propan-1-sulfónico (vemurafenib), o una sal farmacéuticamente aceptable de esta, en donde el primer comprimido y el segundo comprimido comprenden una preparación combinada para usar de modo concurrente o secuencial en el tratamiento de melanoma irresecable o metastásico positivo para la mutación BRAFV⁶⁰⁰, en donde se administran uno o varios primeros comprimidos para proporcionar una dosis total de 60 mg de cobimetinib, los días 1 - 21 de un ciclo de 28 días, y en donde se administran uno o varios segundos comprimidos para proporcionar una dosis total de 960 mg de vemurafenib, dos veces por día, cada día del ciclo de 28 días. Reivindicación 60: Un kit que comprende: (1) un primer comprimido de acuerdo con cualquiera de las reivindicaciones 41, 42 ó 46 a 48; y (2) un segundo comprimido que comprende {3-[5-(4-clorofenil)-1H-pirrolo[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propan-1-sulfónico (vemurafenib), o una sal farmacéuticamente aceptable de esta.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186556P | 2015-06-30 | 2015-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105184A1 true AR105184A1 (es) | 2017-09-13 |
Family
ID=56373188
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101961A AR105184A1 (es) | 2015-06-30 | 2016-06-29 | Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos |
| ARP210100699A AR121624A2 (es) | 2015-06-30 | 2021-03-19 | Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100699A AR121624A2 (es) | 2015-06-30 | 2021-03-19 | Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10478400B2 (es) |
| EP (3) | EP4272735A1 (es) |
| JP (3) | JP6914202B2 (es) |
| KR (1) | KR20180021814A (es) |
| CN (2) | CN108135854B (es) |
| AR (2) | AR105184A1 (es) |
| AU (2) | AU2016287422B2 (es) |
| BR (1) | BR112017028218A2 (es) |
| CA (1) | CA2987912C (es) |
| ES (2) | ES2969014T3 (es) |
| HK (1) | HK1254389A1 (es) |
| HR (2) | HRP20240045T1 (es) |
| IL (2) | IL256299B2 (es) |
| MX (3) | MX2017016163A (es) |
| PL (2) | PL3316867T3 (es) |
| SI (2) | SI3316867T1 (es) |
| TW (3) | TWI804919B (es) |
| WO (1) | WO2017004122A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10751288B2 (en) * | 2016-08-23 | 2020-08-25 | New Jersey Institute Of Technology | Dry processed surface coated engineering excipients |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2019073331A2 (en) * | 2017-10-13 | 2019-04-18 | Unichem Laboratories Ltd | PHARMACEUTICAL COMPOSITIONS OF APREMILAST |
| CN110151763A (zh) * | 2019-06-26 | 2019-08-23 | 深圳市第三人民医院 | 考比替尼作为制备治疗结核病药物中的应用 |
| GB201913972D0 (en) | 2019-09-27 | 2019-11-13 | Univ Ulster | Pharmaceutical Delivery Device and method of manufacture |
| BR112022024533A2 (pt) * | 2020-06-19 | 2022-12-27 | Glaxosmithkline Ip No 2 Ltd | Formulação compreendendo daprodustat |
| WO2023145486A1 (ja) * | 2022-01-28 | 2023-08-03 | 沢井製薬株式会社 | フェソテロジンフマル酸塩含有製剤の製造方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2698560B1 (fr) * | 1992-11-30 | 1995-02-03 | Virbac Laboratoires | Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications. |
| TWI415635B (zh) * | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| CN101222911A (zh) * | 2005-07-15 | 2008-07-16 | 特瓦制药工业有限公司 | 新的制粒方法及由此制备的颗粒 |
| EA025871B9 (ru) | 2005-10-07 | 2017-08-31 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
| US8146000B1 (en) | 2005-10-07 | 2012-03-27 | Goodwell Technologies, Inc. | Integrated transactional workflows distributed across multiple contact centers |
| WO2008044111A1 (en) * | 2006-10-13 | 2008-04-17 | Pfizer Products Inc. | Pharmaceutical formulation tablet |
| EP2190417A2 (en) * | 2008-03-26 | 2010-06-02 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue |
| AU2009292615B2 (en) * | 2008-09-17 | 2015-12-03 | Mylan Inc. | Granulates, process for preparing them and pharmaceutical products containing them |
| CN102802613A (zh) * | 2009-06-22 | 2012-11-28 | 惠氏有限责任公司 | 布洛芬钠片剂和制备包含布洛芬钠的药物组合物的方法 |
| EP2481411A1 (en) * | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib |
| WO2012164060A1 (en) * | 2011-06-03 | 2012-12-06 | F. Hoffmann-La Roche Ag | Methods of treating mesothelioma with a pi3k inhibitor compound |
| WO2013082511A1 (en) * | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
| CA2861594A1 (en) * | 2011-12-27 | 2013-07-04 | Celgene Corporation | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione |
| NZ702244A (en) * | 2012-06-08 | 2017-06-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| BR112015003418A2 (pt) * | 2012-08-17 | 2017-07-04 | Hoffmann La Roche | produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica. |
| CR20200237A (es) | 2012-10-12 | 2020-07-26 | Exelixis Inc | Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer (diviisional 2015-0245) |
| UA114948C2 (uk) * | 2013-03-06 | 2017-08-28 | Новартіс Аг | Склади з органічними сполуками |
| TWI680760B (zh) * | 2013-07-12 | 2020-01-01 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合 |
| EA201690127A1 (ru) * | 2013-07-30 | 2016-07-29 | Джилид Коннектикут, Инк. | Состав на основе ингибиторов syk |
| WO2015091305A1 (en) * | 2013-12-16 | 2015-06-25 | F. Hoffmann-La Roche Ag | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
| AR105483A1 (es) * | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2016
- 2016-06-29 EP EP23198295.0A patent/EP4272735A1/en active Pending
- 2016-06-29 TW TW110125560A patent/TWI804919B/zh active
- 2016-06-29 SI SI201631201T patent/SI3316867T1/sl unknown
- 2016-06-29 TW TW105120582A patent/TWI795344B/zh active
- 2016-06-29 AR ARP160101961A patent/AR105184A1/es not_active Application Discontinuation
- 2016-06-29 KR KR1020187001936A patent/KR20180021814A/ko not_active Application Discontinuation
- 2016-06-29 MX MX2017016163A patent/MX2017016163A/es unknown
- 2016-06-29 WO PCT/US2016/039960 patent/WO2017004122A1/en active Application Filing
- 2016-06-29 IL IL256299A patent/IL256299B2/en unknown
- 2016-06-29 EP EP16736730.9A patent/EP3316867B1/en active Active
- 2016-06-29 CN CN201680049896.XA patent/CN108135854B/zh active Active
- 2016-06-29 HR HRP20240045TT patent/HRP20240045T1/hr unknown
- 2016-06-29 PL PL16736730T patent/PL3316867T3/pl unknown
- 2016-06-29 ES ES21160939T patent/ES2969014T3/es active Active
- 2016-06-29 AU AU2016287422A patent/AU2016287422B2/en active Active
- 2016-06-29 JP JP2017567355A patent/JP6914202B2/ja active Active
- 2016-06-29 CA CA2987912A patent/CA2987912C/en active Active
- 2016-06-29 CN CN202111338132.1A patent/CN114177157A/zh active Pending
- 2016-06-29 EP EP21160939.1A patent/EP3881833B1/en active Active
- 2016-06-29 BR BR112017028218A patent/BR112017028218A2/pt not_active Application Discontinuation
- 2016-06-29 IL IL303352A patent/IL303352A/en unknown
- 2016-06-29 PL PL21160939.1T patent/PL3881833T3/pl unknown
- 2016-06-29 ES ES16736730T patent/ES2871175T3/es active Active
- 2016-06-29 SI SI201631791T patent/SI3881833T1/sl unknown
- 2016-06-29 TW TW112105396A patent/TW202337463A/zh unknown
-
2017
- 2017-12-13 MX MX2020013162A patent/MX2020013162A/es unknown
- 2017-12-13 MX MX2022015606A patent/MX2022015606A/es unknown
- 2017-12-22 US US15/852,125 patent/US10478400B2/en active Active
-
2018
- 2018-10-19 HK HK18113466.8A patent/HK1254389A1/zh unknown
-
2019
- 2019-11-15 US US16/685,284 patent/US20200085749A1/en not_active Abandoned
-
2021
- 2021-03-19 AR ARP210100699A patent/AR121624A2/es unknown
- 2021-05-17 JP JP2021083489A patent/JP7232284B2/ja active Active
- 2021-05-24 HR HRP20210828TT patent/HRP20210828T1/hr unknown
-
2022
- 2022-02-17 AU AU2022201067A patent/AU2022201067A1/en not_active Abandoned
- 2022-04-15 US US17/722,158 patent/US20220339111A1/en active Pending
-
2023
- 2023-02-17 JP JP2023023139A patent/JP2023071769A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105184A1 (es) | Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos | |
| CY1115652T1 (el) | Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες | |
| JP2020506918A (ja) | 特定の胃腸部位での制御放出の剤形 | |
| CA2987114A1 (en) | Method of 3d printing oral dosage forms having a drug in a compartment sealed by an erodible plug | |
| SI2529622T1 (en) | Bruton tyrosine kinase inhibitors | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| CN106236715A (zh) | 药品剂型及其使用 | |
| HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
| RU2016152167A (ru) | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения | |
| JP2016513724A5 (es) | ||
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| BRPI0513598A (pt) | formas de dosagem em comprimidos revestidos de liberação entérica | |
| JP2013209384A5 (es) | ||
| SI2729130T1 (en) | Combined formulations of darunavir | |
| MY157186A (en) | Drug delivery system for administration of poorly water soluble pharmaceutically active substances | |
| JP2012505830A5 (es) | ||
| RU2016103764A (ru) | Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан | |
| JP2017512194A5 (es) | ||
| WO2007120838A3 (en) | Rapidly disintegrating solid oral dosage form of liquid dispersions | |
| HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice | |
| JP2015120758A5 (es) | ||
| JP2017531042A5 (es) | ||
| Hardenia et al. | Formulation and optimization of fast dissolving tablets of promethazine theoclate using 32 factorial design | |
| Jain et al. | Formulation, development and evaluation of gastroretentive sustained release tablets of lansoprazole using natural polymer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |